Imeik Technology Development Co (300896) Q4 2025 earnings summary

Executive summary

• Revenue for 2025 was ¥2.45 billion, down 18.94% year-over-year; net profit attributable to shareholders was ¥1.29 billion, down 34.05% year-over-year.

• Gross margin declined from 94.64% to 92.70%, reflecting increased competition and market pressure.

• The company completed the acquisition of REGEN (Korea), adding global products AestheFill and PowerFill to its portfolio.

• R&D investment reached ¥359.7 million, 14.67% of revenue, with 61 new patent applications and 22 SCI articles published.

• New products, including Minoxidil topical solution and botulinum toxin, received regulatory approval and will expand the product matrix.

Financial highlights

• Operating income: ¥2.45 billion, down 18.94% year-over-year.

• Net profit attributable to shareholders: ¥1.29 billion, down 34.05% year-over-year.

• Operating cash flow: ¥1.32 billion, down 31.29% year-over-year.

• Basic and diluted EPS: ¥4.28, down 34.15% year-over-year.

• Total assets: ¥8.91 billion, up 6.80% from prior year-end.

• Net assets attributable to shareholders: ¥7.58 billion, down 2.73% from prior year-end.

• Quarterly revenue and profit declined sequentially throughout the year.

Outlook and guidance

• The company expects the medical aesthetics industry to maintain a 10% CAGR through 2028, despite a shift from rapid expansion to high-quality growth.

• Strategic focus will be on R&D innovation, international expansion, and full-category product ecosystem development.

• 2026 plans include further global integration, new product launches, and digital transformation of marketing and service platforms.